Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Post-transplant anti-A antibody titers
Timeframe: post-op day 5 or day 12
Primary graft dysfunction grade
Timeframe: post-op day 0, 1, 2, 3
Incidence of hyperacute antibody-mediated rejection
Timeframe: post-op day 1, 2
C4d positivity on transbronchial biopsy samples
Timeframe: 1 year
Incidence and severity of acute cellular rejection
Timeframe: 1 year
Bleeding
Timeframe: post-op day 1-7
Infection
Timeframe: 10 years
Graft function
Timeframe: 10 years
Incidence of malignancy
Timeframe: 10 years
Chronic lung allograft dysfunction
Timeframe: 10 years
Time to death or re-transplantation
Timeframe: 10 years